Two well-known YAP1 inhibitors, verteporfin (VP) and CA3 (CIL56), were demonstrated to effectively reduce the expression levels of both YAP1 and STK3 in the GC cell lines MKN28 and NCI-N87 (Fig. 1G-H). This evidence concerns the gene STK3 and gastric cancer.